Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.

Slides:



Advertisements
Similar presentations
The ENCORE Study Cardiovascular Benefits Associated With the DASH Diet Alone and in Combination with Exercise and Weight Reduction in Men and Women with.
Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
Inactive lifestyle. Risk!! Inactive life style = the same risk as hypertension Inactive life style = the same risk as cholesterol Inactive life style.
Assessment of Overweight and Obesity and the Need for Weight Loss Dr. David L. Gee FCSN/PE 446 Nutrition, Weight Control & Exercise.
Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.
CONTROLLING YOUR RISK FACTORS Taking the Steps to a Healthy Heart.
10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
1 The Atkins Nutritional Approach is an Effective Tool for Treating Metabolic Syndrome X A GP’s perspective Dr Sarah Brewer.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Obesity, Overweight and Weight Control Healthy Weight Network.
ADVICE. Advice Strongly advise adherence to diet and medication Smoking cessation, exercise, weight reduction Ensure diabetes education and advise Diabetes.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
Baseline. Caloric Balance Caloric Intake + Expenditure = +/- Caloric Balance.
The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
I CAN Prevent Diabetes! Individuals and Communities Acting Now to Prevent Diabetes Recruitment Discussion 2012.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
HEALTHY EATING And LIVING Kenneth E. Nixon MD. Problem Overweight and Obesity 97 million adults are overweight or obese Medical Problems Associated with.
Look AHEAD Study Lukasz Materek Endocrinology Rounds May 20, 2012.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Anthropometrics in Obesity Robert Kushner, MD Northwestern University Feinberg School of Medicine.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Modern Management of Cholesterol in the High-Risk Patient.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
Obesity Surgery : Is it only for losing weight ? Joint Hospital Surgical Grand Round Simon Chu Prince of Wales Hospital.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Type 2 Diabetes – A Global Epidemic Arya M Sharma, MD, FRCP(C) Professor of Medicine Research Chair for Obesity Research & Management University of Alberta.
A.P.J. Houdijk Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
A Diabetes Outcome Progression Trial
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 2 of 4.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
Diabetes Prevention Program (DPP)
Obesity. Step 1:Identifying Patients Who Need to Lose Weight Measure height and weight and calculate BMI at annual visits or more frequently. Use the.
CHAPTER 7: Obesity in Women. Introduction 68% of U.S. population is overweight or obese. Resulting medical and psychosocial difficulties can be debilitating.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Risk Factors: Measure and Modify Nina Radford MD Cardiovascular Medicine Department Director, Clinic Research Cooper Clinic, Dallas Texas.
Iris Shai, R.D., Ph.D., Dan Schwarzfuchs, M.D., Yaakov Henkin, M.D., Danit R. Shahar, R.D., Ph.D.,,etc The Dietary Intervention Randomized Controlled Trial.
 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.
Source: LIFESTYLE MODIFICATION IN THE PREVENTION OF TYPE 2 DIABETES: THE EXPERIENCE WITH THE DIABETES PREVENTION PROGRAM AND LOOK.
The ACCORD Trial: Review of Design and Results
Chapter 4 Where Are You.
ACCORD Design and Baseline Characteristics
Presenter: Gary Foster, PhD – Professor of Medicine and Public Health
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
The Hypertension in the Very Elderly Trial (HYVET)
Section overview: Cardiometabolic risk reduction
Baseline Characteristics of the Subjects*
Obesity Eppie Habashi.
Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.
Presentation transcript:

Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center Baton Rouge, LA

OUTLINE  The relationship between weight and diabetes  Look AHEAD – what it means for obesity and for diabetes  Looking ahead – what have we learned to date from the study?

There is a diabetes epidemic. Crude and Age-Adjusted Prevalence of Diagnosed Diabetes per 100 Population, US, Source: CDC website

There is an obesity epidemic. Prevalence of Overweight and Obesity by Age, Source CDC/NCHS, Health, US, 2006

Relationship Between BMI and Risk of Type 2 Diabetes Chan J et al. Diabetes Care 1994;17:961. Colditz G et al. Ann Intern Med 1995;122:481. Age-Adjusted Relative Risk Body Mass index (kg/m 2 ) MenWomen <22<

Relationship Between Weight Gain in Adulthood and Risk of Type 2 Diabetes Mellitus Relative Risk Weight Change (kg) Willett et al. N Engl J Med 1999;341: MenWomen

Weight Loss Benefits  For acute weight loss phase: Strong benefit in glycemic control Reduction in LDL, reduction in HDL, reduction in BP  For reduced stable weight: Strong benefit in glycemic control Increase in HDL, reduction in BP; ~20% weight loss is needed to see reduction in LDL

Mechanisms of Glycemia Improvement with Weight Loss  Negative energy balance during acute weight loss improves glycemia  After weight loss plateaus, reduced state with less visceral adiposity improves glycemia  The behaviors that promote weight loss maintenance, low fat diet, energy neutral diet, & physical activity improve glycemia.

Insulin Sensitivity Improves with Weight Loss in Patients with Type 2 Diabetes Insulin (pmol/L) Before Weight Loss at 1 Year (%) Wing et al. Arch Intern Med 1987;147:1749. *P<0.01 vs before. * * * >15

DPP Results Diabetes Prevention Program Research Group. N Engl J. Med 2002: 346, 393. Diet + Exercise Diabetes Incidence per 100 Persons-Years Placebo Metformin 58% reduction

Redrawn from: Hamman, et al Diabetes Care 29: , 2006 Change in weight from baseline (kg) Incidence rate per 100 person-years How much weight loss is needed to prevent type 2 diabetes – the DPP experience

Adding it up  Being obese is bad for you. Overweight and obesity are associated with increased mortality.  Is losing weight good for you? Losing weight is associated with Improvements in risk factors Prevention of diabetes But what about reduction in mortality? The SOS study showed mortality reduction with intentional, surgical weight loss, but many epi studies show that weight loss is associated with increased mortality.

OUTLINE  The relationship between weight and diabetes  Look AHEAD – what it means for obesity and for diabetes  Looking ahead – what have we learned to date from the study?

Why conduct the Look AHEAD Study?  Randomized clinical trial of a lifestyle intervention designed to produce and maintain weight loss and effects on so-called hard endpoints – cardiovascular events and mortality. Look AHEAD also gathers data on benefits/risks over 14 years in diabetics.  Look AHEAD is important to everyone in the weight loss community.  Look AHEAD is important to everyone in the diabetes community.

OUTLINE  The relationship between weight and diabetes  Look AHEAD – what it means for obesity and for diabetes  Looking ahead – what have we learned to date from the study?

Study Design  5145 overweight subjects with type 2 diabetes  2 arms Usual care (Diabetes Support and Education) Usual care + Lifestyle Intervention  Study duration: up to 13.5 years (with 4 years of intensive intervention).  Primary outcome: Cardiovascular death (fatal MI and stroke), nonfatal MI, and stroke; hospitalization for angina Look AHEAD Research Group. Controlled Clin Trials. 2003;24:61-28.

Lifestyle Intervention: Phase I, Weight Loss Induction Months 1-6 Weekly contact  3 group sessions/month  1 individual session/month Personal weight loss goal = 10% Study weight loss goal > 7% Phase II, Weight Loss Maintenance Months 7-12 Reduced contact  2 group sessions/month  1 individual session/month  2 face-to-face contacts/month required; 3 recommended Individual weight loss goal  continue weight loss if < 10%  weight maintenance if > 10%

Diabetes Support and Education  3-4 meetings / year to promote retention  health education topics diet exercise social support

Attendance At Year 1 Examination ILI Cohort: 97% DSE Cohort: 96% P=0.004

% Weight Loss at 1-Year -9 ILI DSE p < % Weight Change 8.6% 0.7%

% Reduction in Initial Weight by Gender N=872 N=1229 N=1197 N= Months % Reduction in Initial Weight Men Women P<0.001

Weight Loss in Insulin Users vs. Non- Users within ILI Group Mean % Weight Loss 7.6% 8.7% Medication Use At Baseline P=0.002

Fitness Change (%) at 1-Year Mean % Fitness Change Unadjusted P<0.001 Adjusted for 1 Year Weight Change P< DSEILI DSE

1-Year Changes in Markers of Diabetes Control Markers of Diabetes Control ILIDSEP-value Hemoglobin A1c (%), BL Hemoglobin A1c (%), Y1 Y1 – Baseline <0.001 Fasting glucose (mg/dl), BL Fasting glucose (mg/dl), Y1 Y1 – Baseline <0.001 Diabetes medications, BL Diabetes medications, Y1 Y1 – Baseline 86.5% 78.6% -7.8% 86.5% 88.7% 2.2% 0.93 <0.001

1-Year Changes in Markers of Blood Pressure Control Markers of Blood Pressure Control ILIDSEP-value Systolic BP (mmHg), BL Systolic BP (mmHg), Y1 Y1 – Baseline <0.001 Diastolic BP (mmHg), BL Diastolic BP (mmHg), Y1 Y1 – Baseline <0.001 Antihypertensive medications, BL Antihypertensive medications, Y1 Y1 – Baseline 75.3% 75.2% -0.1% 73.7% 75.9% 2.2%

1-Year Changes in Markers of Lipid Control Markers of Lipid ControlILIDSEP-value LDL-cholesterol (mg/dl), BL LDL-cholesterol (mg/dl), Y1 Y1 – Baseline HDL-cholesterol (mg/dl), BL HDL-cholesterol (mg/dl), Y1 Y1 – Baseline <0.001 Triglycerides (mg/dl), BL Triglycerides (mg/dl), Y1 Y1 – Baseline <0.001 Lipid lowering medications, BL Lipid lowering medications, Y1 Y1 – Baseline 49.4% 53.0% 3.7% 48.4% 57.8% 9.4% 0.52 <0.001

1-Year Changes in Percent of Participants Meeting ADA Goals ADA GoalILIDSEP-value Hemoglobin A1c < 7%, BL Hemoglobin A1c < 7%, Y1 Y1 – Baseline 46.3% 72.7% 26.4% 45.4% 50.8% 5.4% 0.50 <0.001 Blood pressure < 130/80 mmHg, BL Blood pressure < 130/80 mmHg, Y1 Y1 – Baseline 53.5% 68.6% 15.1% 49.9% 57.0% 7.0% 0.01 <0.001 LDL-cholesterol < 100 mg/dl, BL LDL-cholesterol < 100 mg/dl, Y1 Y1 – Baseline 37.1% 43.8% 6.7% 36.9% 44.9% 8.0% All three goals, BL All three goals, Y1 Y1 – Baseline 10.8% 23.6% 12.8% 9.5% 16.0% 6.5% 0.13 <0.001

Trying Look AHEAD at Home  The ILI was a program Derived from DPP Manuals for interventionists and participants  Dietary Intake kcal/day < 250 lb kcal/day > 250 lb < 30% calories from fat Meal replacements Menu plans provided  Physical Activity Gradual increases to 175 min/wk 10,000 steps

Trying Look AHEAD at Home Algorithm for medication management while in negative energy balance. Obesity Vol 14 No 5 May, 2006

Thank you